Effect of different durations of using a standing frame on the rate of hip migration in children with moderate to severe cerebral palsy: a feasibility study for a randomised controlled trial.

Cerebral palsy Children Feasibility study Hip dysplasia Paediatric Standing frame

Journal

Physiotherapy
ISSN: 1873-1465
Titre abrégé: Physiotherapy
Pays: England
ID NLM: 0401223

Informations de publication

Date de publication:
09 2022
Historique:
received: 07 09 2020
revised: 23 07 2021
accepted: 19 01 2022
pubmed: 14 5 2022
medline: 3 8 2022
entrez: 13 5 2022
Statut: ppublish

Résumé

To assess the feasibility of a randomised controlled trial (RCT) to evaluate the effect of different doses of standing time on hip migration rate in children with cerebral palsy (CP). Children aged 1-12 years with CP GMFCS levels III-V were recruited and randomised to either doubling or continuing with their usual time in their standing frame. Caregivers kept a standing time diary. The primary outcome measure was Reimers hip migration percentage, measured at baseline, 12 and 24 months. A blinded assessor measured secondary clinical outcomes at baseline, 6 and 12 months. Feasibility results are reported following CONSORT guidelines. Twenty-five children were recruited. Nineteen were randomised and 10 completed the 12-month intervention. The mean daily standing time in the intervention group was 49minutes (SD 39.1) (Monday-Sunday) and 58.1 (SD 44.1) minutes during weekdays. In children remaining in the trial, primary and secondary clinical outcome measures were available in 54% and 90% of children respectively. There were three serious adverse events, unrelated to standing. It may be feasible to conduct an RCT to assess the effect of duration of standing on hip migration in children with CP with an altered protocol. The suggested target dose is 60minutes five times per week compared to a control group standing for 30minutes three times per week, over twelve months. Use of botulinum toxin need not be a criterion for exclusion and radiography should be included as a research cost. NHS Health Research Committee, South West ethics approval (ref 13/SW/0228).

Identifiants

pubmed: 35550486
pii: S0031-9406(22)00001-3
doi: 10.1016/j.physio.2022.01.001
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

42-49

Informations de copyright

Crown Copyright © 2022. Published by Elsevier Ltd. All rights reserved.

Auteurs

R Rapson (R)

University of Plymouth, Derriford Road, Devon, PL6 8BH, UK. Electronic address: Rachel.rapson@nhs.net.

T King (T)

Multiple Sclerosis and Health Measurement Research and Innovation, Faculty of Medicine and Dentistry, University of Plymouth, Devon, PL4 8AA, UK.

C Morris (C)

University of Exeter Medical School, Devon, EX2 4TE, UK.

R Jeffery (R)

University Hospitals Plymouth, Devon, PL6 8DH, UK.

J Mellhuish (J)

University of Plymouth, Derriford Road, Devon, PL6 8BH, UK.

C Stephens (C)

University of Plymouth, Derriford Road, Devon, PL6 8BH, UK.

J Marsden (J)

School of Health Professions, University of Plymouth, Derriford Road, Devon, PL6 8BH, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH